Phase III development of Antisoma's ASA404 in lung cancer extended to Japan
Glyn Edwards, Antisoma's CEO, said "We're pleased that Japanese lung cancer patients can now participate in this key phase III trial of ASA404. This is an important step towards a potential application to market the drug in Japan."
ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) which selectively disrupts tumour blood vessels, generating tumour death (necrosis) due to the resulting lack of blood flow in the tumour. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.